Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.
Status:
RECRUITING
Trial end date:
2030-09-30
Target enrollment:
Participant gender:
Summary
Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for severe acute COVID-19 infection and are experiencing long-haul symptoms. The symptoms of long COVID can include extreme tiredness (fatigue), shortness of breath, memory and concentration issues (brain fog), heart palpitations, dizziness, joint pain, muscle aches, cough, headaches, anxiety, and depression.
It's important to note that there are various other symptoms that individuals can experience after a COVID-19 infection, such as loss of smell, chest pain or tightness, difficulty sleeping (insomnia), pins and needles, depression, anxiety, tinnitus, earaches, nausea, diarrhea, stomach aches, loss of appetite, cough, headaches, sore throat, and changes to the sense of smell or taste.
To be included in the study, participants must have had symptoms for more than 4 weeks. The goal of the study is to measure biomarkers, identify new ones through clinical trials, and individualize and optimize treatment plans, which may or may not include COVID-19 post-market antivirals, vaccines, and medical care.
It's essential to conduct thorough clinical trials to understand the long-term effects of COVID-19 and to develop personalized treatment plans for individuals experiencing long-haul symptoms.
Phase:
PHASE4
Details
Lead Sponsor:
Well- Konnect Healthcare Services and Research Firm
Collaborator:
All of Us Research Program at the National Institute of Health
Treatments:
2019-nCoV Vaccine mRNA-1273 DNA, Recombinant nirmatrelvir and ritonavir drug combination Psychotherapy